Active not recruiting
A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer
J1O-MC-JZHB - ClinicalTrials.gov - NCT03898791
The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine in participants with platinum-sensitive, extensive-stage small-cell lung cancer.
How long will I be in the trial?
Your participation in this trial could last up to 20 months, depending on how you and your tumor respond.
Active not recruiting
A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer
J1O-MC-JZHB - ClinicalTrials.gov - NCT03898791
The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine in participants with platinum-sensitive, extensive-stage small-cell lung cancer.
How long will I be in the trial?
Your participation in this trial could last up to 20 months, depending on how you and your tumor respond.
Key Requirements
Age :
18+
Sex:
All
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18+
Sex
All
Participants must
Participants must have histological or cytological evidence of a diagnosis of platinum sensitive small cell lung cancer that is extensive stage
Participants must have adequate organ function
Participants must have a performance status (PS) of ≤1 on the Eastern Cooperative Oncology Group (ECOG) scale
Participants must have discontinued previous treatments for cancer.
Participants must be able to swallow capsules
Participants must NOT
Participants must not be currently enrolled in a clinical study
Participants must not have a serious concomitant systemic disorder
Participants must not have a symptomatic human immunodeficiency virus infection or symptomatic activated/reactivated hepatitis B or C
Participants must not have a significant cardiac condition
Participants must not have previously received an aurora kinase inhibitor
Trial Summary
Conditions the trial is for
Small Cell Lung Cancer
What the trial is testing?
LY3295668 Erbumine
Could I receive a Placebo?
no
Enrollment Goal
64
Trial Dates
July 2019 - December 2021
Trial Phase
1
Enter your postal code to find the nearest site
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18+
Sex
All
Participants must
Participants must have histological or cytological evidence of a diagnosis of platinum sensitive small cell lung cancer that is extensive stage
Participants must have adequate organ function
Participants must have a performance status (PS) of ≤1 on the Eastern Cooperative Oncology Group (ECOG) scale
Participants must have discontinued previous treatments for cancer.
Participants must be able to swallow capsules
Participants must NOT
Participants must not be currently enrolled in a clinical study
Participants must not have a serious concomitant systemic disorder
Participants must not have a symptomatic human immunodeficiency virus infection or symptomatic activated/reactivated hepatitis B or C
Participants must not have a significant cardiac condition
Participants must not have previously received an aurora kinase inhibitor
Trial Summary
Conditions the trial is for
Small Cell Lung Cancer
What the trial is testing?
LY3295668 Erbumine
Could I receive a Placebo?
no
Enrollment Goal
64
Trial Dates
July 2019 - December 2021
Trial Phase
1
Not the right fit? Sign up to receive updates on new trials.
Trial Locations
Hide locations not currently recruiting
Enter your postal code to see sites near you
Small Cell Lung Cancer Resources
